Granted Patent
B2
US 9,296,810 · App. 12/989,494 · Granted Mar 29, 2016
Fibronectin-based binding molecules and uses thereof
Assignee:
NOVARTIS AG
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The invention provides fibronectin type III (Fn3)-based binding molecules that bind to a specific target antigen. The invention further provides bispecific Fn3-based binding molecules that bind to two or more targets simultaneously. The Fn3-based binding molecules of the invention can also be linked together to form multispecific Fn3-based binding molecules, and/or can be conjugated to a non-Fn3 moiety, such as, Human Serum Albumin (HSA), for improved half life and stability. The invention also provides methods for generating, screening and using Fn3-based binding molecules in a variety of therapeutic and diagnostic applications.
Claims (1)
1. An Fn3-based binding molecule comprising SEQ ID NO: 120.
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Dec 8, 2010
From: HASTEWELL, JOHN; LOEW, ANDREAS
To: NOVARTIS AG
Reel/Frame 025478/0068 →
Continuity (2)
Provisional Application
61050142
· May 2, 2008